A citation-based method for searching scientific literature

Richard J Caselli, Jessica Langbaum, Gary E Marchant, Rachel A Lindor, Katherine S Hunt, Bruce R Henslin, Amylou C Dueck, Jason S Robert. Mayo Clin Proc 2014
Times Cited: 31







List of co-cited articles
192 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Disclosure of APOE genotype for risk of Alzheimer's disease.
Robert C Green, J Scott Roberts, L Adrienne Cupples, Norman R Relkin, Peter J Whitehouse, Tamsen Brown, Susan LaRusse Eckert, Melissa Butson, A Dessa Sadovnick, Kimberly A Quaid,[...]. N Engl J Med 2009
317
54

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Reisa A Sperling, Paul S Aisen, Laurel A Beckett, David A Bennett, Suzanne Craft, Anne M Fagan, Takeshi Iwatsubo, Clifford R Jack, Jeffrey Kaye, Thomas J Montine,[...]. Alzheimers Dement 2011
45

Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease.
Elizabeth M Wikler, Robert J Blendon, John M Benson. Alzheimers Res Ther 2013
27
37

Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.
Serena Chao, J Scott Roberts, Theresa M Marteau, Rebecca Silliman, L Adrienne Cupples, Robert C Green. Alzheimer Dis Assoc Disord 2008
162
25

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.
Keith A Johnson, Satoshi Minoshima, Nicolaas I Bohnen, Kevin J Donohoe, Norman L Foster, Peter Herscovitch, Jason H Karlawish, Christopher C Rowe, Maria C Carrillo, Dean M Hartley,[...]. Alzheimers Dement 2013
279
25

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.
Kristin Harkins, Pamela Sankar, Reisa Sperling, Joshua D Grill, Robert C Green, Keith A Johnson, Megan Healy, Jason Karlawish. Alzheimers Res Ther 2015
50
25

A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure.
B R Ott, M A Pelosi, G Tremont, P J Snyder. Alzheimers Dement (N Y) 2016
15
53

Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results.
Jonathan Gooblar, Catherine M Roe, Natalie J Selsor, Matthew J Gabel, John C Morris. JAMA Neurol 2015
20
40

Should we disclose amyloid imaging results to cognitively normal individuals?
Joshua D Grill, David K Johnson, Jeffrey M Burns. Neurodegener Dis Manag 2013
23
30

Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors.
Jill S Goldman, Susan E Hahn, Jennifer Williamson Catania, Susan LaRusse-Eckert, Melissa Barber Butson, Malia Rumbaugh, Michelle N Strecker, J Scott Roberts, Wylie Burke, Richard Mayeux,[...]. Genet Med 2011
171
22


Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
Willemijn J Jansen, Rik Ossenkoppele, Dirk L Knol, Betty M Tijms, Philip Scheltens, Frans R J Verhey, Pieter Jelle Visser, Pauline Aalten, Dag Aarsland, Daniel Alcolea,[...]. JAMA 2015
748
22

The A4 study: stopping AD before symptoms begin?
Reisa A Sperling, Dorene M Rentz, Keith A Johnson, Jason Karlawish, Michael Donohue, David P Salmon, Paul Aisen. Sci Transl Med 2014
422
22

Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.
J Scott Roberts, Laura B Dunn, Gil D Rabinovici. Neurodegener Dis Manag 2013
31
22

Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.
S A S A Bemelmans, K Tromp, E M Bunnik, R J Milne, S Badger, C Brayne, M H Schermer, E Richard. Alzheimers Res Ther 2016
33
22

Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials.
Scott Y H Kim, Jason Karlawish, Benjamin E Berkman. Neurology 2015
28
25

Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project.
Craig W Ritchie, José Luis Molinuevo, Luc Truyen, Andrew Satlin, Serge Van der Geyten, Simon Lovestone. Lancet Psychiatry 2016
118
19

Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
Yen Ying Lim, Paul Maruff, Christine Getter, Peter J Snyder. Alzheimers Dement 2016
35
19

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
Randall J Bateman, Chengjie Xiong, Tammie L S Benzinger, Anne M Fagan, Alison Goate, Nick C Fox, Daniel S Marcus, Nigel J Cairns, Xianyun Xie, Tyler M Blazey,[...]. N Engl J Med 2012
16

Using AD biomarker research results for clinical care: a survey of ADNI investigators.
Melanie B Shulman, Kristin Harkins, Robert C Green, Jason Karlawish. Neurology 2013
27
18

Public beliefs and knowledge about risk and protective factors for Alzheimer's disease.
J Scott Roberts, Sara J McLaughlin, Cathleen M Connell. Alzheimers Dement 2014
41
16

Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults.
Tara T Lineweaver, Mark W Bondi, Douglas Galasko, David P Salmon. Am J Psychiatry 2014
60
16

Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment.
Joshua D Grill, Jason Karlawish, David Elashoff, Barbara G Vickrey. Alzheimers Dement 2013
24
20

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.
L A Farrer, L A Cupples, J L Haines, B Hyman, W A Kukull, R Mayeux, R H Myers, M A Pericak-Vance, N Risch, C M van Duijn. JAMA 1997
16

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.
Bruno Dubois, Howard H Feldman, Claudia Jacova, Harald Hampel, José Luis Molinuevo, Kaj Blennow, Steven T DeKosky, Serge Gauthier, Dennis Selkoe, Randall Bateman,[...]. Lancet Neurol 2014
16

Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.
Joshua D Grill, Yan Zhou, David Elashoff, Jason Karlawish. Neurobiol Aging 2016
20
25

Safety of disclosing amyloid status in cognitively normal older adults.
Jeffrey M Burns, David K Johnson, Edward P Liebmann, Rebecca J Bothwell, Jill K Morris, Eric D Vidoni. Alzheimers Dement 2017
36
16

Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents.
Peter J Neumann, Joshua T Cohen, James K Hammitt, Thomas W Concannon, Hannah R Auerbach, Chihui Fang, David M Kent. Health Econ 2012
83
12

Disclosure of amyloid imaging results to research participants: has the time come?
Jennifer H Lingler, William E Klunk. Alzheimers Dement 2013
29
13

Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease.
J Scott Roberts, Susan A LaRusse, Heather Katzen, Peter J Whitehouse, Melissa Barber, Stephen G Post, Norman Relkin, Kimberly Quaid, Robert H Pietrzak, L Adrienne Cupples,[...]. Alzheimer Dis Assoc Disord 2003
64
12

Effect of Alzheimer disease genetic risk disclosure on dietary supplement use.
Jacqueline A Vernarelli, J Scott Roberts, Susan Hiraki, Clara A Chen, L Adrienne Cupples, Robert C Green. Am J Clin Nutr 2010
48
12

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.
Clifford R Jack, David S Knopman, William J Jagust, Leslie M Shaw, Paul S Aisen, Michael W Weiner, Ronald C Petersen, John Q Trojanowski. Lancet Neurol 2010
12

Revising the definition of Alzheimer's disease: a new lexicon.
Bruno Dubois, Howard H Feldman, Claudia Jacova, Jeffrey L Cummings, Steven T Dekosky, Pascale Barberger-Gateau, André Delacourte, Giovanni Frisoni, Nick C Fox, Douglas Galasko,[...]. Lancet Neurol 2010
12

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Marilyn S Albert, Steven T DeKosky, Dennis Dickson, Bruno Dubois, Howard H Feldman, Nick C Fox, Anthony Gamst, David M Holtzman, William J Jagust, Ronald C Petersen,[...]. Alzheimers Dement 2011
12


The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Guy M McKhann, David S Knopman, Howard Chertkow, Bradley T Hyman, Clifford R Jack, Claudia H Kawas, William E Klunk, Walter J Koroshetz, Jennifer J Manly, Richard Mayeux,[...]. Alzheimers Dement 2011
12

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Bruno Dubois, Harald Hampel, Howard H Feldman, Philip Scheltens, Paul Aisen, Sandrine Andrieu, Hovagim Bakardjian, Habib Benali, Lars Bertram, Kaj Blennow,[...]. Alzheimers Dement 2016
679
12

APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts.
Jing Qian, Frank J Wolters, Alexa Beiser, Mary Haan, M Arfan Ikram, Jason Karlawish, Jessica B Langbaum, John M Neuhaus, Eric M Reiman, J Scott Roberts,[...]. PLoS Med 2017
73
12

Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.
José L Molinuevo, Jordi Cami, Xavier Carné, Maria C Carrillo, Jean Georges, Maria B Isaac, Zaven Khachaturian, Scott Y H Kim, John C Morris, Florence Pasquier,[...]. Alzheimers Dement 2016
28
14

Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.
Jessica Mozersky, Pamela Sankar, Kristin Harkins, Sara Hachey, Jason Karlawish. JAMA Neurol 2018
30
13

The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis.
Gareth J Hollands, David P French, Simon J Griffin, A Toby Prevost, Stephen Sutton, Sarah King, Theresa M Marteau. BMJ 2016
244
12

The neuropsychology of normal aging and preclinical Alzheimer's disease.
Richard J Caselli, Dona E C Locke, Amylou C Dueck, David S Knopman, Bryan K Woodruff, Charlene Hoffman-Snyder, Rosa Rademakers, Adam S Fleisher, Eric M Reiman. Alzheimers Dement 2014
45
9

Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.
A M Saunders, W J Strittmatter, D Schmechel, P H George-Hyslop, M A Pericak-Vance, S H Joo, B L Rosi, J F Gusella, D R Crapper-MacLachlan, M J Alberts. Neurology 1993
9

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Victor L Villemagne, Samantha Burnham, Pierrick Bourgeat, Belinda Brown, Kathryn A Ellis, Olivier Salvado, Cassandra Szoeke, S Lance Macaulay, Ralph Martins, Paul Maruff,[...]. Lancet Neurol 2013
9

Biomarker modeling of Alzheimer's disease.
Clifford R Jack, David M Holtzman. Neuron 2013
502
9

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.
Clifford R Jack, David A Bennett, Kaj Blennow, Maria C Carrillo, Howard H Feldman, Giovanni B Frisoni, Harald Hampel, William J Jagust, Keith A Johnson, David S Knopman,[...]. Neurology 2016
593
9

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.
Stephanie Jb Vos, Chengjie Xiong, Pieter Jelle Visser, Mateusz S Jasielec, Jason Hassenstab, Elizabeth A Grant, Nigel J Cairns, John C Morris, David M Holtzman, Anne M Fagan. Lancet Neurol 2013
353
9

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
E H Corder, A M Saunders, W J Strittmatter, D E Schmechel, P C Gaskell, G W Small, A D Roses, J L Haines, M A Pericak-Vance. Science 1993
9

Tau positron emission tomographic imaging in aging and early Alzheimer disease.
Keith A Johnson, Aaron Schultz, Rebecca A Betensky, J Alex Becker, Jorge Sepulcre, Dorene Rentz, Elizabeth Mormino, Jasmeer Chhatwal, Rebecca Amariglio, Kate Papp,[...]. Ann Neurol 2016
523
9

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.
Tiia Ngandu, Jenni Lehtisalo, Alina Solomon, Esko Levälahti, Satu Ahtiluoto, Riitta Antikainen, Lars Bäckman, Tuomo Hänninen, Antti Jula, Tiina Laatikainen,[...]. Lancet 2015
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.